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Abstract
Tip60 (KAT5) is a histone acetyltransferase (HAT enzyme) involved in multiple cellular processes including transcriptional
regulation, DNA damage repair and cell signalling. In prostate cancer, aggressive cases over-express Tip60 which functions
as an androgen receptor co-activator via direct acetylation of lysine residues within the KLKK motif of the receptor hinge
region. The purpose of this study was to identify and characterise a Tip60 acetylase inhibitor. High-throughput screening
revealed an isothiazole that inhibited both Tip60 and p300 HAT activity. This substance (initially identified as 4-methyl-5-
bromoisothiazole) and other isothiazoles were synthesised and assayed against Tip60. Although an authentic sample of 4-
methyl-5-bromoisothiazole was inactive against Tip60, in an in vitro HAT assay, 1,2-bis(isothiazol-5-yl)disulfane (NU9056) was
identified as a relatively potent inhibitor (IC50 2 mM). Cellular activity was confirmed by analysis of acetylation of histone and
non-histone proteins in a prostate cancer cell line model. NU9056 treatment inhibited cellular proliferation in a panel of
prostate cancer cell lines (50% growth inhibition, 8–27 mM) and induced apoptosis via activation of caspase 3 and caspase 9
in a concentration- and time-dependent manner. Also, decreased androgen receptor, prostate specific antigen, p53 and p21
protein levels were demonstrated in response to treatment with NU9056. Furthermore, pre-treatment with NU9056
inhibited both ATM phosphorylation and Tip60 stabilization in response to ionising radiation. Based on the activity of
NU9056 and the specificity of the compound towards Tip60 relative to other HAT enzymes, these chemical biology studies
have identified Tip60 as a potential therapeutic target for the treatment of prostate cancer.
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Introduction
Histone acetylation and deacetylation are key events in the
regulation of chromatin structure. Histone acetyltransferases
(HATs) catalyze the addition of acetyl groups to the e-amino
terminus of lysine residues within histones. Acetylation results in
an open chromatin structure by removing positive charges from
histones, thus inducing protein conformational changes, which
allows transcriptional machinery to access the DNA and promote
transcriptional activity. Histone deacetylases (HDAC) oppose this
process by promoting a closed chromatin structure, which is
transcriptionally repressed. Furthermore, histone acetylation
marks can function as docking sites for other proteins to interpret
the ‘histone code’; for example, the tripartite motif containing 24
(TRIM24) was recently described as a ‘reader’ protein, which
recognises both unmodified histone H3 at lysine 4 and histone H3
acetylated at lysine 23 on the same histone tail resulting in
increased gene expression [1]. In addition, non-histone proteins
such as p53 [2,3], ataxia telangiectasia mutated (ATM) [4] and
androgen receptor (AR) [5,6] can also be acetylated resulting in
altered protein activity. Hence, protein acetylation and deacetyla-
tion can have significant effects on cell function, and for cells to
maintain normal growth and differentiation it is important that
these two functions maintain equilibrium. In support of this
concept, HDAC inhibitors have been found to have wide ranging
cellular effects and clinical activity in leukaemia [7,8], with
Vorinostat (SAHA) being approved for clinical use in this disease.
Modulation of histone acetylation clearly has therapeutic poten-
tial.
Tip60, recently renamed KAT5, is a member of the MYST
family of HAT enzymes first identified in 1996 [9]. Since then
many cellular functions have been found to use this protein. Loss
of Tip60 results in impaired DNA repair, as this HAT is activated
in response to ionising radiation (IR), causing acetylation of
histones and activation of p53 and ATM [4]. Inhibition of Tip60
should therefore sensitise cells to DNA damaging agents used as
cancer therapeutics. Tip60 also functions in the NF-kB pathway,
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via interactions with B-cell CLL/lymphoma 3 (BCL-3) [10] and
cAMP-dependent signalling [11]. Furthermore, Tip60 can func-
tion as a co-activator for a number of steroid hormone receptors
including the AR, which is involved in the development and
progression of prostate cancer (CaP). Studies have shown that AR
can be acetylated by a number of HAT enzymes, including p300,
p300/CBP-associated factor (PCAF) and Tip60, to increase its
transcriptional activity [6,12]. AR acetylation is thought to
regulate the recruitment of co-activators to the transcriptional
machinery of androgen responsive genes [13]. Additionally, Tip60
is functionally up-regulated in clinical CaP specimens and
expression correlates with disease progression [14]. In contrast,
one report suggested that Tip60 is required to express the tumour
metastasis suppressor KAI1 in CaP cell lines, suggesting that
Tip60 is a tumour suppressor [15]. Similarly, a Tip60 gene
knockout study proposed Tip60 as a haplo-insufficient tumour
suppressor at pre and early-tumoral stages of lymphoma, breast
and head and neck cancers [16]. However, studies on clinical
prostate specimens contradict this suggestion and support Tip60 as
an oncogene in CaP [13,17]. Thus, targeting the acetylase activity
of Tip60 could be a useful therapeutic strategy in CaP.
A small number of HAT inhibitors have been reported.
Coupling a histone H3 peptide to CoA to form a bisubstrate
inhibitor of HAT activity has been described; however, the
compound has poor cell membrane permeability [18]. The natural
products anacardic acid and garcinol are HAT inhibitors that are
cell permeable; they sensitise cells to IR, which could be useful as a
combination therapy for cancer treatment. Other inhibitors of
HAT function include a-methylene butyrolactones [19], benzyli-
dene acetones [20] and alkylidene malonates [21]. More recently,
isothiazolones, which covalently bind to the HAT active site thiol,
have been described as an effective starting point for molecular
modelling-based approaches for generating more potent and
specific inhibitors [22–24]. In the current study we employed a
high throughput screening approach to identify selective inhibitors
of Tip60. Based on the lead molecule, structurally related
compounds were generated and tested for HAT inhibition and
Tip60 specificity in order to identify a molecular tool for studies in
cell line models of CaP.
Results
High Throughput Screen (HTS) and Hit Validation
A high throughput screening campaign for Tip60 inhibitors was
conducted at OSI Pharmaceuticals Ltd. Assays based on the
ALPHATM screen and DELFIATM formats were developed and
used to screen a structurally diverse compound collection
(,80,000 members). A number of hits were identified from the
primary ALPHATM screen. However, most of these did not show
significant activity in the secondary screen. A single compound
OXA-10 (initially identified as 4-methyl-5-bromoisothiazole, 1),
was identified as a hit in both screens and the activity was
replicated with repurchased material. Repurchased OXA-10
showed activity against Tip60 (IC50 1.1 mM - Figure 1) and
p300 (IC50 2.7 mM) (Table 1), but not other histone acetyltrans-
ferases, e.g. PCAF and GCN5 (IC50.100 mM). LC-MS analysis of
the repurchased sample of OXA-10 indicated the presence of
,80% 4-methyl-5-bromoisothiazole 1, but showed that it
contained ,20% of an unknown impurity. In order to validate
1 as the active inhibitor of Tip60 in OXA-10, the synthesis of 1
was undertaken, along with analogues, in order to develop
structure activity relationships. Details of the chemical synthesis
(Figure 2) can be found in Supplementary Information.
Specificity of NU9056 for Tip60 Acetyltransferase
NU9056 (7), as well as compounds 5 and 6, were tested for in
vitro activity against a panel of recombinant HAT enzymes,
including p300, PCAF and GCN5, to determine whether they
show greater specificity towards Tip60 than compound 1. ICR
CCT129182, which has been shown to have inhibitory activity
against p300 and PCAF, was also tested [24]. A number of
compounds were found to inhibit the activity of Tip60 at low
micromolar concentrations (Figure 1; Supplemental Figure S1).
However, specificity towards Tip60 over other HAT enzymes
tested was found to be greatest with compound 7 (NU9056) as
shown in Table 1 (16.5-, 29- and .50-fold for selectivity for Tip60
over PCAF, p300 and GCN5, respectively).
NU9056 Inhibits Protein Acetylation in Prostate Cancer
Cell Lines
Tip60 acetylates histone proteins, specifically histones H4 and
H2A, in a nucleosomal context [25]. Furthermore, in vitro studies
have demonstrated that Tip60 can also acetylate core histones
H2A (Lys 5), H3 (Lys 14) and H4 (Lys 5, Lys 8, Lys 12 and Lys 16)
[26,27]. To test whether NU9056 could inhibit acetylation of
endogenous proteins targeted by Tip60, LNCaP cells were used as
these are a representative model of androgen dependent CaP. The
acetylation status of histone H4 at lysine 8 (H4K8) and 16
(H4K16) and histone H3 at lysine 14 (H3K14) was investigated in
these cells by Western blotting. In addition, the level of Tip60 was
assessed following treatment with NU9056 and the control
compound, 1,2-bis(4-pyridyl)ethane (Figure 3A) demonstrating
that Tip60 levels themselves are unaffected. As the basal levels of
these acetylated histone marks are quite low, the HDAC inhibitor
trichostatin A (TSA) was introduced to remove the influence of
HDAC activity on acetylation in the cellular assay. In the presence
of TSA alone, acetylation was increased at H4K8, H4K16 and
H3K14 (Figure 3B), consistent with previous reports [28–30].
Increasing concentrations of NU9056 resulted in decreased levels
of acetylated histone H4K16, H3K14 and H4K8, targets for
Tip60-mediated acetylation (Figure 3C). Furthermore, the control
compound, 1,2-bis(4-pyridyl)ethane, did not affect any of the
histone modifications studied.
To define further the HAT inhibitory activity of NU9056,
acetylation of the non-histone protein a-tubulin was also investigated.
When LNCaP cells were incubated with NU9056 (24 mM) for 24
hours a decrease in acetylated tubulin was observed. However, by 72
hours acetylation had returned to basal levels (Figure 3D). To confirm
that this effect was due to NU9056, acetylated tubulin was monitored
but no change in levels was observed within 6 hours unlike alterations
to histone modifications (Figure 3E). Densitometry for all Western blots
is shown in Supplemental Figure S2.
NU9056 Inhibits Cell Growth
We observed that knockdown of Tip60 in LNCaP cells resulted in
an inhibition of cell proliferation by approximately 33% (p-
value= 0.0019) (Figure 4A). Efficient knockdown of Tip60 mRNA
in these cells was confirmed by real-time PCR (Figure 4B, 70%
knockdown; p-value= 0.0313) and Western blotting (Figure 4C). If
NU9056 action was mediated through inhibiting Tip60 enzymatic
activity, inhibition of cell proliferation by NU9056 would be
expected. Indeed, proliferation was found to be reduced in the
presence of NU9056 in all CaP cell lines tested as measured by
sulforhodamine B (SRB) assay (Table 2, Supplementary Figure S3,
S4). Interestingly LNCaP cells, which are androgen responsive and
express a mutated but functional AR as well as wild type p53, and
the bone metastasis derived PC3 cells, which do not express a
Tip60 Inhibition in Prostate Cancer
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functional AR and are p53 null, displayed similar GI50 concentra-
tions (24 mM 62 and 27 mM 62 for LNCaP and PC3 cells,
respectively). However, LNCaP-AI cells, a sub-line of LNCaP cells
serially maintained in steroid-depleted media, which still express a
functional AR and are a model of castrate resistant CaP post
androgen ablation therapy, have a lower GI50 (24 mM 62 and
16 mM61 for LNCaP and LNCaP-AI, respectively). Other cell line
models of androgen independence, e.g. LNCaP-CdxR, which is
serially maintained in the presence of bicalutamide and CWR22rv1,
show significantly greater sensitivity to NU9056 than the parental
LNCaP cell line (GI50 values of 12 mM 62.5 and 7.5 mM 60.2
(p,0.05 and p,0.0005, respectively)). Tip60 levels were measured
by Western blotting in these cell lines (Figure 4D) to reveal that the
most sensitive cell line, CWR22rv1, actually expresses the most
Tip60.
To test whether NU9056 can reduce the survival of CaP cells,
colony forming ability was evaluated following exposure of LNCaP
cells to 24 mM (GI50) NU9056 for 24 hours. Colony forming
ability was reduced following NU9056 exposure, which was
statistically significant (p,0.05) (Figure 4E).
Figure 1. Table of Tip60 IC50 values of isothiazoles and related compounds. To assess the activity against Tip60 HAT, in vitro HAT assays
using 3H acetyl-CoA were carried out using histones as substrates. Assays were performed in quadruplicate and repeated twice. For compounds
producing.50% inhibition at 100 mM, IC50 values were calculated. Individual IC50 values are presented. For other compounds the % inhibition at 100
mM is presented.
doi:10.1371/journal.pone.0045539.g001
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NU9056 Treatment Causes Apoptosis via Caspase
Activation
The effects of NU9056 on cell cycle phase distribution and
apoptosis induction were also tested in LNCaP cells. To assess
apoptotic effects, FACS analysis for activated caspase 3 and
activated caspase 9 was used. NU9056 resulted in both caspase 3
and caspase 9 activation in a time- and concentration-dependent
manner (Figure 5A, Supplementary Figures S5 and S6). The levels
of apoptosis were also compared with other HAT inhibitors
demonstrating that NU9056, with its greater specificity for Tip60,
can induce apoptosis at similar levels to the more promiscuous
inhibitors (Supplementary Figure S7). Analysis of the sub-G1
population in LNCaP cells (Figure 5B) confirmed the induction of
apoptosis in a time- and concentration-dependent manner for
NU9056. However, under no conditions of exposure to NU9056
did we observe any G1 or G2M cell cycle arrest in LNCaP cells;
only accumulation in the sub-G1 phase was seen (Figure 5C, D).
To determine whether castrate resistant cell lines are more
sensitive to NU9056 as suggested by GI50 determination a
comparison of LNCaP cells with LNCaP-AI and LNCaP-CdxR
cells after treatment with NU9056 for 24 hours was carried out.
Indeed, LNCaP-AI and LNCaP-CdxR cells appear to be more
sensitive to NU9056 than LNCaP cells as shown by a greater
population being in the Sub-G1 phase of the cell cycle (Figure 5E).
Upon using the LNCaP GI75 dose (36 mM) a significant increase in
Sub-G1 was seen in LNCaP-AI cells (p = 0.036) compared to
LNCaP cells. Similar trends were seen for LNCaP-CdxR although
this was not statistically significant (p = 0.1679).
NU9056 Treatment Reduces PSA Expression in LNCaP
Cells
Tip60 has been reported as an AR co-activator [31], which
plays a role in CaP development. To confirm the role of Tip60 in
PSA expression, siRNA was used to knockdown Tip60 levels in
LNCaP cells and PSA mRNA levels monitored in response to
androgen (dihydrotestosterone (DHT)) stimulation. In the pres-
ence of a non-silencing siRNA PSA was induced by approximately
10-fold in response to DHT (Figure 6A). However, after
knockdown of Tip60 (Figure 6B) only a 2.5 fold increase was
observed (Figure 6A). To investigate the effects of NU9056 on AR
function, LNCaP cells were treated with 24 mM NU9056 over a
48 hour period, whereupon levels of AR and PSA protein were
assessed by Western blotting. In addition, we investigated the
levels of p53 and its target gene p21, as p53 is also a target for
Tip60. We discovered that the levels of both AR and p53 were
reduced after 24 hours by 2- and 3-fold respectively, and that the
products of the target genes, p21 and PSA, were also reduced by 3-
and 2-fold respectively (Figure 6C,D). This result suggests that
indeed Tip60 is involved in AR and p53 signalling in this cell line
and that NU9056 may, by modulating Tip60 acetylation activity,
affect these important downstream targets.
NU9056 Inhibits the DNA Damage Response in Prostate
Cancer Cells
Tip60 is known to play a role in the DNA damage response
[25]. Upon exposure to IR Tip60 is activated, which results in
acetylation of histone proteins and activation of ATM and p53 [4].
To test whether NU9056 could inhibit the DNA damage response
via inhibition of Tip60 acetylase activity, the activation of ATM
was assessed by Western blotting in response to IR after pre-
treatment with NU9056. In response to IR, pATM levels were
increased dramatically within 10 minutes. Over time pATM levels
gradually fell. However, in the presence of NU9056 this decrease
was much faster (Figure 7A). Furthermore, in response to IR levels
of Tip60 protein were stabilised resulting in accumulation. Cells
which were pre-treated with NU9056 did not demonstrate Tip60
accumulation (Figure 7B), which may explain higher turnover of
pATM levels.
Tip60 acetylase activity is required to facilitate the ubiquitin
ligase UBC13-mediated ubiquitination and subsequent destruction
of cH2AX [32]. Therefore, inhibition of Tip60 acetylase activity
will prevent the down-regulation of the cH2AX signal. To test
this, 293T cells were treated with NU9056 (24 mM) or vehicle
control for 1 hour prior to IR (2 Gy) exposure. The cells were then
fixed and cH2AX foci visualised by immunofluorescence.
Compared to vehicle control, cH2AX formation was still clearly
enriched as much as 24 hours after IR stimulation (Figure 7C)
suggesting that the repair of DNA damage is impaired. This is also
seen in LNCaP and LNCaP-CdxR cells which were assessed by
flow cytometry for cH2AX. In LNCaP cells, the number of foci
were significantly higher after 24 hours recovery in the presence of
inhibitor (p = 0.0277) (Figure 7D) whilst in LNCaP-CdxR cells a
significant difference is seen after 4 hours recovery (p = 0.0324)
(Figure 7E). An increase in cH2AX is also seen at 24 hours
recovery but was found not to be statistically significant.
Discussion
Protein acetylation, as a regulatory mechanism, is proving to be
important in many cellular pathways, not just gene transcription
via histone modification. Both sets of enzymes responsible for
regulating acetylation, HATs and HDACs, are de-regulated in
disease states. Therefore, targeting both types of enzymes with
small molecule inhibitors as a therapeutic strategy is valid.
Inhibitors against HDACs have been found to be successful in
clinical trials; however, HAT inhibitors are at an earlier stage of
development. Recently, there have been some putative HAT
inhibitors described, although none appear able to distinguish
significantly between the different HAT family members and none
have been specifically developed against Tip60, a HAT enzyme
which appears to play a particular role in CaP development and
progression. To address this point, we identified a HAT inhibitor,
using HTS and targeted compound synthesis, which inhibits
Tip60 over other HAT enzymes.
The requirement to fully validate HTS hits through resynthesis
is widely accepted as material in commercial compound collec-
Table 1. IC50 values of 1,2-bis(isothiazol-5-yl)disulfane (7) and
related compounds towards HATs.
Compound HAT IC50 (mM)
Tip60 p300 PCAF GCN5
1,2-Bis(isothiazol-5-yl)disulfane
(NU9056, 7)
,2, 2 60, 58 30, 36 .100
5-Thiocyanato-isothiazole (6) .100 – – –
1,2-Bis(4-methylisothiazol-5-yl)disulfane
(5)
4, 4 58, 43 33, 25 .100
OXA-10 1.1 2.7 .100 .100
ICR CCT129182 1, 0.9 31, 28 23, 30 .100
AE562 0.8, 0.8 1.8, 2 .100 .100
To assess the activity against Tip60 HAT, in vitro HAT assays using 3H acetyl-CoA
were carried out using histones as substrates. Assays were performed in
quadruplicate and repeated twice. Individual IC50 values are presented.
doi:10.1371/journal.pone.0045539.t001
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tions may include unidentified impurities, or may degrade on
storage, typically as frozen DMSO solutions, giving false positives.
In this case, a literature synthesis for 1 was not available and a
route had to be developed. The first scheme attempted (Part 1) did
not give the target compounds, 1, or its desmethyl analogue;
however, the isocyanato and disulfide analogues 4–7 were
prepared. Compound 1 was prepared successfully via an
alternative route (Part 2).
The biological activity observed for the disulfides 5 and 7
(NU9056), prompted us to investigate the activity of other simple
aromatic and heteroaromatic disulfides. Interestingly, these
compounds were devoid of Tip60 inhibitory activity, indicating
that Tip60 inhibition is not solely due to the presence of the
disulfide group. Similarly, the bromothiophene analogue of
isothiazole 1 was inactive.
Isothiazolones have been previously reported to target the
acetylase activity of many HAT enzymes including p300 and
PCAF [24]. However, a specific inhibitor for Tip60 has not been
described. There are many benefits to be gained by targeting this
protein due to the diverse cellular processes in which Tip60 is
implicated. For example, not only does this protein function to
increase the transcriptional activity of AR and p53, but it can also
play a role in DNA repair where it can acetylate histone proteins
to mark sites of DNA damage and activate ATM [25].
In this report, we have prepared an isothiazolone compound,
NU9056 (7) that targets Tip60 HAT activity selectively resulting in
reduced acetylation of histone proteins in vitro. Tip60 has been
found to be aberrantly expressed in a number of cancers, including
prostate and skin cancers. Specifically, Tip60 can acetylate the
AR, a key transcription factor in CaP, to promote increased AR
transcriptional activity [6] and Tip60 expression has also been
shown to correlate with disease progression [14]. Thus, targeting
the acetylase activity of this protein could be beneficial to patients
suffering with castrate resistant CaP that no longer responds to
androgen deprivation therapy. Therefore, to test the ability of
NU9056 to inhibit HAT activity in cells we have used CaP cell line
models. In these cell lines we have demonstrated the inhibitory
effect of NU9056 against the HAT activity of Tip60. Furthermore,
acetylation of non-histone proteins such as tubulin was found to be
reduced in these cell lines in response to NU9056. Interestingly,
the levels of AR and p53 decreased slightly after NU9056
treatment in LNCaP cells supporting previous reports that
acetylation enhances the stability of these proteins [33,34]. Due
to the importance of AR and p53 and their presence in LNCaP
cells, this may explain why both apoptosis is increased and
proliferation is decreased in response to NU9056 in a concentra-
tion and time dependent manner. Nevertheless, there are
differences in the sensitivity between different CaP cell lines which
cannot be explained solely by AR or p53 status. This latter
observation suggests that the activity of Tip60 towards AR and
p53 is not a contributing factor to the cellular response to the drug.
However in response to DNA damaging IR, which activates the
acetylase activity of Tip60, we find that NU9056 inhibits the
development of the pATM signal and impedes the stabilisation of
Tip60 itself, potentially via inhibition of auto-acetylation. Fur-
thermore, NU9056 impairs cell survival in response to IR and
impairs the removal of the cH2AX mark potentially hindering
DNA repair.
Figure 2. Chemical synthesis of Tip60 inhibitors. Part 1 - Synthesis of compounds 4–7. Part 2 - Synthesis of Compounds 1 and 11.
doi:10.1371/journal.pone.0045539.g002
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Interestingly, cell line models of castrate resistance appear to be
more sensitive to NU9056. Increased levels and stability of Tip60
in androgen-insensitive cells, due to chronic growth in androgen
ablated conditions, has been reported in other similar cell line
models [35], human CaP xenografts and biopsy samples from
castrate resistant patients [14]. It is possible that androgen-
insensitive cells are more dependent on Tip60 levels for their
growth, compared to their androgen responsive counterparts,
resulting in greater sensitivity to NU9056. Indeed, initial studies
show that the levels of Tip60 protein vary between the cell lines
tested, with the more NU9056 sensitive cell lines, CWR22rv1 and
LNCaP-CdxR demonstrating the highest levels of Tip60. Differ-
ences in enzymatic activity of Tip60 between cell lines may also be
important. This hypothesis should be fully tested in future studies
in a number of cell lines and in vivo model systems to conclusively
determine the mechanism of sensitivity. As to whether NU9056 is
generally toxic to the cells; we believe that this is unlikely for the
most part. Firstly, there was no change in cH2AX staining when
NU9056 was applied to cells suggesting no induction of DNA
damage. Secondly differential effects were seen depending on the
cell line suggesting generally toxicity was not the cause of
Figure 3. NU9056 inhibits protein acetylation in prostate cancer cell lines. LNCaP cells were treated with increasing concentrations of
NU9056 or the control compound, 1,2 bis(4-pyridyl)-ethane for 24 hours. (A) Levels of Tip60 were assessed by Western blotting. (B) LNCaP cells were
treated with 2 mM TSA for 6 hours and levels of histone H4 acetylated-lysine 16, histone H4 acetylated-lysine 8 and histone H3 acetylated lysine 14
were assessed by Western blotting. LNCaP cells were treated with increasing concentrations of NU9056 or the control compound for 2 hours, then
treated with the HDAC inhibitor TSA (2 mM) for a further 4 hours. (C) Levels of histone H4 acetylated-lysine 16, histone H4 acetylated-lysine 8 and
histone H3 acetylated lysine 14 were assessed by Western blotting. (D) LNCaP cells were treated with 24 mM NU9056 over 4 days and the levels of
acetylated tubulin were assessed by Western blotting. (E) LNCaP cells were treated with increasing concentrations of NU9056 or the control
compound for 2 hours, then treated with the HDAC inhibitor TSA (2 mM) for a further 4 hours. Levels of acetylated tubulin were assessed by Western
blotting. Alpha-tubulin was used as a loading control. Representative blots are shown for duplicate experiments.
doi:10.1371/journal.pone.0045539.g003
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detrimental cellular effects. However, at higher doses a role for
general toxicity may become apparent.
Overall, a therapeutic role for Tip60 inhibitors in the treatment
of castrate resistant CaP is supported by the chemical biology and
molecular genetic studies described in this paper.
Materials and Methods
Reagents and Antibodies
NU9056, 1,2-bis(4-pyridyl)-ethane (Sigma) and related com-
pounds were dissolved in DMSO as 10 mmol/L stocks and stored
at 220uC. Anti-histone H4-acetyl lysine 8 (ab15823), acetyl lysine
16 (ab61240) and Anti-histone H3-acetyl lysine 14 (ab61232)
antibodies were obtained from AbCam (Cambridge, UK). Anti-
Tip60 (07-038) antibody was obtained from Millipore (MA, USA).
Anti-androgen receptor (G122-77) antibody was obtained from
BD (NJ, USA). Anti-PSA (C-19; sc7638) antibody was obtained
from Santa Cruz Biothechnologies (USA). Anti-alpha tubulin
clone DM1A (T9026), anti-acetylated tubulin clone 6-11B-1
(T7451) antibodies were obtained from Sigma (MO, USA). Anti-
p53 (Do-1) and anti-p21 (Ab-4) antibodies were obtained from
Calbiochem (Germany).
Cell Culture
Tissue culture reagents were purchased from Sigma. LNCaP,
CWR22Rv1 and PC3 cells, obtained from the American Type
Culture Collection (Manassas, VA, USA), were maintained in
RPMI 1640 media supplemented with 10% (v/v) fetal calf serum
(FCS), and 2 mM L-glutamine at 37uC in 5% CO2 atmosphere.
LNCaP-AI and LNCaP-cdxR cells were generated and main-
tained as previously described [14,36].
Synthesis of HAT Inhibitors
This is described in detail in supplementary materials and
methods.
In vitro Histone Acetyl-transferase Assay
HAT assays were performed as previously described [37].
Briefly, HAT assay buffer (50 mM Tris pH 8, 0.5 mM EDTA
Figure 4. Knockdown of Tip60 reduces proliferation in LNCaP cells. (A) To confirm that inhibition of Tip60 can reduce cellular proliferation
2.5 nM siRNA specifically targeted against Tip60 in LNCaP cells or a non-silencing control was used. Proliferation was determined by sulforhodamine
B (SRB) assays at 3 control proliferation doubling times after siRNA transfection in normal growth media. To confirm Tip60 knockdown, RNA was
collected at 96 hours from a parallel experiment and assessed for Tip60 expression using (B) real-time PCR and (C) Western blotting. (D) Tip60 levels in
prostate cancer cell lines were assessed by Western blotting. (E) Prostate cancer cell survival was assessed by treating LNCaP cells with 24 mM NU9056
for 24 hours then plating at varying cell densities (36103, 1.66104 and 36104) and allowing colonies to form over 2 weeks. Colonies were then fixed
with Carnoy’s fixative and stained with crystal violet. Colonies were then counted and colony forming efficiency calculated. The mean of 3
experiments 6 standard deviation is shown on bar charts. *p-value ,0.05.
doi:10.1371/journal.pone.0045539.g004
Table 2. Growth inhibition (GI) concentrations of NU9056 in
prostate cancer cell lines.
n=3 LNCaP LNCaP-AI LNCaP-CdxR CWR22rv1 PC3
GI10 (mM) 261 563 661 260.1 666
GI25 (mM) 1761 1466 8.361.4 3.960.2 17.661.3
GI50 (mM) 24±2 16±1 12±2.5* 7.5±0.2*** 27±2
GI75 (mM) 3661 - 1362 1863 3161
Experiments were performed as 6 replicates, repeated on 3 independent
occasions. Sensitivity to NU9056 compared to LNCaP cells was determined by T-
test.
*,0.05,
***,0.0005.
doi:10.1371/journal.pone.0045539.t002
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Figure 5. NU9056 reduces LNCaP cell survival by inducing apoptosis. (A) LNCaP cells were seeded onto 6 well plates for 24 hours, then
increasing doses of NU9056 were applied for (i) 24 hours, (ii) 96 hours or (iii) GI25 (17 mM) or (iv) GI50 (24 mM) was applied over 4 days. All cells were
collected and fixed with cytofix/cytoperm (BD) then caspase 3 and caspase 9 assay kits (BD) were used to assess their activity by flow cytometry.
Fluorescence was detected on the FL-1 channel of the FACSCAN. (B) Analysis of the SubG1 population was performed on these same cells using
propidium iodide to stain cellular DNA. LNCaP cells were seeded onto 6 well plates for 24 hours, then NU9056 was applied for (C) 1 or (D) 4 days. (E)
LNCaP, LNCaP-AI and LNCaP-CdxR cells were seeded out onto 6 well plates and NU9056 was applied for 24 hours. Analysis of SubG1 was performed
as described above. All cells were collected and fixed with cytofix/cytoperm (BD) then cell cycle analysis was performed using propidium iodide to
stain cellular DNA. All FACS data was analysed using WinMDI. All experiments were performed 3 times and the mean 6 standard error is shown. *p-
value ,0.05; **p-value ,0.005; ***p-value ,0.001.
doi:10.1371/journal.pone.0045539.g005
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pH 8, 10% glycerol), histones (Sigma) and recombinant HAT
enzymes (produced and purified as described in supplementary
materials and methods) were combined with putative HAT
inhibitor molecules and incubated at room temperature for
10 mins. 3H acetyl-CoA was added and incubated at 30uC for
30 minutes. Samples were blotted onto filter paper, washed and
dried. Scintillation counts were detected using a Wallac 1450
Microbeta Trilux liquid scintillation and a luminescence counter.
Assays were performed in quadruplicate.
Western Blotting
All cell lysates for Western analyses were collected in SDS
loading buffer (0.125 M Tris pH 6.8, 2% SDS, 10% (v/v) glycerol,
10% (v/v) b-mercaptoethanol, and 0.01% (w/v) bromophenol
blue). Samples were separated by SDS-PAGE prior to transfer to
nitrocellulose membrane (Hybond-C, Amersham). Membranes
were blocked with 5% (w/v) MarvelTM at room temperature for 1
hour, incubated with primary antibody overnight at 4uC followed
by incubation with the appropriate horseradish peroxidise
conjugated secondary antibody (Dako). Proteins of interest were
visualised with ECL reagent (Amersham, UK).
Sulforhodamine B Growth Inhibition Assays
Cells were seeded into 96-well plates at a density appropriate for
exponential growth at the beginning of the assay. After overnight
attachment, cells were treated with NU9056 over a range of
concentrations for 3 days (equivalent to approximately 3
population doubling times). Cells were then fixed in 10% (w/v)
TCA and stained with sulforhodamine B (SRB) as previously
described [38]. The concentrations required to inhibit cell growth
by 50% (GI50) were calculated using GraphPad Prism (San Diego,
CA, USA) software.
Colony Forming Assay
LNCaP cells were seeded out onto 90 mm dishes, exposed to
increasing amounts of IR, then re-seeded out at varying cell
densities and incubated for 14 days to allow colony formation.
Medium was then removed and cells gently washed and stained
with crystal violet. Colonies were counted and the surviving
fraction calculated.
FACS Analysis
LNCaP cells were seeded onto 6 well plates and allowed to
attach overnight. The appropriate concentration of NU9056 was
then applied for the indicated time. Medium containing any
floating cells was removed and retained, and cells were trypsinised
from the plates and added to the removed media. Cells were fixed
using 50 ml cytofix/cytoperm (BD) then caspase 3 and caspase 9
assay kits (BD) were used to detect caspase activity, according to
the manufacturer’s protocol. Fluorescence was detected on the FL-
1 channel of FACSCAN. Cell cycle profiles were generated by
propidium iodide staining for 10 minutes in the presence of RNase
and 5% (v/v) Triton.
cH2AX Immunofluorescence
293T cells were seeded onto coverslips in 6 well plates and
allowed to adhere for 24 hours. NU9056 (24 mM) or DMSO was
Figure 6. NU9056 reduces PSA and p53 protein levels. To confirm the effects of Tip60 on androgen receptor activity we used 2.5 nM siRNA
specifically targeted against Tip60 in LNCaP cells, or non-silencing control. Knockdown was achieved after 48 hours in steroid depleted medium after
which time 10 nM DHT was applied to induce androgen receptor activity and PSA expression. RNA was collected after 24 hours DHT stimulation,
reverse transcription and real-time PCR performed. Expression of (A) PSA and (B) Tip60 was normalised relative to HPRT1 expression. (C) LNCaP cells
were treated with 24 mM NU9056 over 48 hours and protein samples were collected in SDS sample buffer. Protein analysis was carried out by SDS
PAGE and Western blotting for p53, p21, AR, PSA and alpha tubulin. (D) Densitometry was performed on Western blots. All experiments were
performed twice and the mean 6 standard deviation is shown.
doi:10.1371/journal.pone.0045539.g006
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Figure 7. NU9056 inhibits Tip60 accumulation and ATM phosphorylation in response to ionising radiation. To demonstrate the
inhibition of Tip60 activity by NU9056, levels of pATM, Tip60 and cH2AX were investigated in response to IR in the presence and absence of drug.
LNCaP cells were treated with 24 mM NU9056 or vehicle control for 1 hour prior to 0.5 Gy IR. Protein lysates were collected at various time points
post-IR and analysed by Western blotting for (A) pATM and (B) Tip60 levels. (C) 293T, (D) LNCaP and (E) LNCaP-CdxR cells were pretreated with
NU9056 (24 mM) or vehicle control for 1 hour prior to 2 Gy IR. Cells were fixed and stained for cH2AX foci over time and foci determined by
immunofluorescence for 293T cells and flow cytometry for LNCaP and LNCaP-CdxR. Experiments were repeated 3 times with representative images
shown and quantified data shown as mean % cells stained for cH2AX 6 standard deviation.
doi:10.1371/journal.pone.0045539.g007
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applied to the cells for 1 hour prior to exposure to 2 Gy IR. Cells
were then fixed in 4% (v/v) paraformaldehyde and stained for
cH2AX as previously described [39] using primary anti-phospho-
histone H2AX (Ser139) antibody (clone JBW301, mouse mono-
clonal antibody; Upstate, Millipore Corp).
cH2AX FACS Analysis
LNCaP cells were seeded onto 6 well plates and allowed to attach
overnight. The appropriate concentration of NU9056 was then
applied for the indicated time. Medium containing any floating cells
was removed and retained, and cells were trypsinised from the plates
and added to the removed media. Cells were fixed using 50 ml cytofix/
cytoperm (BD) then incubated in primary anti-phospho-histoneH2AX
(Ser139) antibody for 2 hours. Cells were then washed twice in 1 X
Permwash (BD) and incubated in secondary rabbit anti-mouse FITC
conjugated antibody (DAKO) for 2 hours in the dark. Fluorescence
was detected on the FL-1 channel of FACSCalibur (BD).
Supporting Information
Figure S1 Inhibition of in vitro HAT activity. In vitro HAT
assays were performed using histone proteins, recombinant HAT
enzymes and 3H acetyl CoA in the presence and absence of HAT
inhibitors. Scintillation counts were detected and % inhibition
calculated. Experiments were performed in quadruplicate and
repeated 3 times. Mean % inhibition was calculated6 standard error
and used to determine IC50 values for each putative HAT inhibitor.
(TIF)
Figure S2 Densitometry of Western blots. Densitometry
was performed using QuantityOne (BioRAD) on Westerns shown
in Figure 2. All data is normalised to background and loading
controls then expressed as fold change compared to DMSO
controls 6 standard deviation.
(TIF)
Figure S3 IC50determination fromLNCaPgrowth curves.
LNCaP cells were seeded out onto 96 well plates and incubated in the
presence of HAT inhibitor for 3 doubling times. Cells were fixed and
sulforhodamine B (SRB)assays performed. Individual experimental
repeats are shown and the corresponding IC50 values.
(TIF)
Figure S4 NU9056 inhibits growth in prostate cancer cell
lines. Prostate cancer cells were seeded out onto 96 well plates and
incubated in increasing concentrations of NU9056 for 3 doubling
times. Cells were then fixed and sulforhodamine B (SRB) assays
performed. Experiments were performed as 6 replicates, repeated on 3
independent occasions. Mean % growth inhibition 6 standard
deviation is shown.
(TIF)
Figure S5 Caspase 9 cleavage in LNCaP cells. LNCaP
cells were seeded onto 6 well plates for 24 hours, then NU9056
was applied for 1–4 days. All cells were collected and fixed with
cytofix/cytoperm (BD) then caspase 9 assay kit (BD) was used to
assess caspase cleavage activity by flow cytometry. Fluorescence
was detected on the FL-1 channel of FACSCAN. Experiments
were repeated 3 times. Data shown are dot plots of 10,000 events
for 1 representative experiment.
(TIF)
Figure S6 Caspase 3 cleavage in LNCaP cells. LNCaP
cells were seeded onto 6 well plates for 24 hours, then NU9056
was applied for 1–4 days. All cells were collected and fixed with
cytofix/cytoperm (BD) then caspase 3 assay kit (BD) was used to
assess caspase cleavage activity by flow cytometry. Fluorescence
was detected on the FL-1 channel of FACSCAN. Experiments
were repeated 3 times. Data shown are dot plots of 10,000 events
for 1 representative experiment.
(TIF)
Figure S7 Caspase 3 cleavage in LNCaP cells in
response to HAT inhibition. LNCaP cells were seeded out
onto 6 well plates and incubated with GI50 concentrations of
HAT inhibitors for 96 hours. Cells were then harvested and
caspase 3 cleavage detected using an anti-cleaved caspase 3 FITC
conjugated antibody and flow cytometry. (A) Mean fold change of
3 experiments 6 standard deviation is shown. (B) Dot plots of
10,000 events are shown for 1 representative experiment.
Docetaxol was included as a positive control to induce apoptosis.
(TIF)
Supplementary Information S1 Additional materials,
methods, results and references.
(DOCX)
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